Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5,766 JPY | -2.72% | -4.85% | +7.94% |
Mar. 27 | Roche's Chugai Wins Japanese Approval for Piasky Injection | MT |
Mar. 04 | Jefferies Adjusts Chugai’s Price Target to 7,000 Yen From 6,200 Yen, Keeps at Buy | MT |
Sales 2023 | 1,111B 7.34B | Sales 2024 * | 1,092B 7.22B | Capitalization | 9,752B 64.42B |
---|---|---|---|---|---|
Net income 2023 | 325B 2.15B | Net income 2024 * | 344B 2.27B | EV / Sales 2023 | 7.24 x |
Net cash position 2023 | 739B 4.88B | Net cash position 2024 * | 802B 5.3B | EV / Sales 2024 * | 8.19 x |
P/E ratio 2023 |
27
x | P/E ratio 2024 * |
28.4
x | Employees | 7,771 |
Yield 2023 |
1.5% | Yield 2024 * |
1.43% | Free-Float | 38.08% |
Latest transcript on Chugai Pharmaceutical Co., Ltd
1 day | -2.72% | ||
1 week | -5.48% | ||
Current month | -3.90% | ||
1 month | -3.21% | ||
3 months | +7.06% | ||
6 months | +24.89% | ||
Current year | +7.94% |
Managers | Title | Age | Since |
---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 60 | 87-03-31 |
Itagaki Toshiaki
DFI | Director of Finance/CFO | - | - |
Hisafumi Okabe
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Masayuki Oku
BRD | Director/Board Member | 79 | 15-02-28 |
Motoo Ueno
BRD | Director/Board Member | 66 | 84-03-31 |
James H. Sabry
BRD | Director/Board Member | 65 | 19-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.57% | 14 M€ | +10.37% | ||
1.87% | 58 M€ | +18.23% | ||
1.53% | 65,729 M€ | +20.95% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 5,766 | -2.72% | 2 396 900 |
24-03-27 | 5,927 | -0.20% | 2,716,800 |
24-03-26 | 5,939 | +1.52% | 2,473,700 |
24-03-25 | 5,850 | -0.53% | 2,178,700 |
24-03-22 | 5,881 | -3.59% | 3,559,200 |
Delayed Quote Japan Exchange, March 28, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.94% | 64.42B | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.18% | 210B | |
+1.43% | 210B | |
-6.54% | 201B | |
-3.51% | 157B |